# Shenzhen Kangtai Biological Products Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/shenzhen-kangtai-biological-products-co

- Industry: Biotechnology
- Headquarters: Shenzhen, China
- Website: www.biokangtai.com
- Total disclosed funding: $76M
- Latest round: Series G (Jun 5, 2015)
- Investors on record: 7

## About

Shenzhen Kangtai Biological Products Co., Ltd, based in China, primarily engages in the development, production and sales of vaccine.

## Funding rounds

- Series G, Jun 5, 2015, $22M — CMB International Asset Management
- Series F, Apr 7, 2015, $11M — Huagai Capital
- Series E, Jan 12, 2015, $2.1M — Frontline BioVentures
- Series D, May 20, 2014, $26M — Panlin Capital
- Series C, May 15, 2012, $7.5M — CAC Capital Management
- Series A, Oct 21, 2002, $7.4M — Beijing High Technology Venture Capital, Hunan Hi-Tech Venture Capital

## Investors

- Beijing High Technology Venture Capital (https://capitalatlas.ai/funds/beijing-high-technology-venture-capital) — Series A
- Hunan Hi-Tech Venture Capital (https://capitalatlas.ai/funds/hunan-hi-tech-venture-capital) — Series A
- CAC Capital Management (https://capitalatlas.ai/funds/cac-capital-management) — Series C
- Panlin Capital (https://capitalatlas.ai/funds/panlin-capital) — Series D
- Frontline BioVentures (https://capitalatlas.ai/funds/frontline-bioventures) — Series E
- Huagai Capital (https://capitalatlas.ai/funds/huagai-capital) — Series F
- CMB International Asset Management (https://capitalatlas.ai/funds/cmb-international-asset-management) — Series G